Sales & Marketing News | pharmaphorum

News

Babylon hires Andrew Hine to spearhead overseas expansion

UK digital health company Babylon has hired Andrew Hine to take charge of its international expansion efforts, as it fights to retain its stock market listing in the US.

News

Merck defends blockbuster Januvia franchise from patent chal...

Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-sell

News

Getting approval will only be the first challenge facing lec...

Biogen and Eisai are riding high on the wave of optimism set in motion by the top-line data drop for Alzheimer's therapy lecanemab – but a number of breakwaters could lie ahead.

News

FDA clears Dupixent as first drug for rare skin disorder

Sanofi and Regeneron have claimed the first approval in the US for a drug for prurigo nodularis, after the FDA gave a green light to Dupixent as a treatment for adults with the rare skin di

News

Whistleblower gets $250m as Biogen settles US kickbacks case

Biogen has finalised a $900 million payment to settle a whistleblower lawsuit claiming that it paid kickbacks to US doctors to prescribe its multiple sclerosis drugs.

News

GSK names Burberry's Julie Brown as its new CFO

GSK has said that its chief financial officer Iain Mackay will stand down from the role in May next year, to be replaced by Julie Brown, currently chief operating and financial officer at l

Babylon hires Andrew Hine to spearhead overseas expansion

Merck defends blockbuster Januvia franchise from patent chal...

Getting approval will only be the first challenge facing lec...

FDA clears Dupixent as first drug for rare skin disorder

Whistleblower gets $250m as Biogen settles US kickbacks case

GSK names Burberry's Julie Brown as its new CFO

Trial miss doesn't dent Biogen's faith in Alzheimer's drug

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks